key: cord-0786887-fykj6t6t
authors: Lefebvre, M.; Vignier, N.; Pitard, B.; Botelho-Nevers, E.; Cohen, R.; Epaulard, O.
title: Covid-19 vaccines: frequently asked questions and updated answers
date: 2021-02-27
journal: Infect Dis Now
DOI: 10.1016/j.idnow.2021.02.007
sha: 239c40db7bac04d2009feeca1d36cf52e483ef92
doc_id: 786887
cord_uid: fykj6t6t

At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named Covid-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective antiviral treatment, and mass vaccination came to be considered as the strategy most likely to put an end to the pandemic. The objective of this text is to address and hopefully answer the questions being put forward by healthcare professionals on the different anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations; we are proposing a report on both today’s state of knowledge, and the 14 February 2021 recommendations of the French health authorities.

and Immunization) and the WHO, the common objective being to accelerate the development and production of diagnostic tools, treatments and Covid-19 vaccines and to ensure equitable access to all of the above.

In the exceptional context of the pandemic, the different vaccine development stages designed to assess safety and effectiveness have swiftly dovetailed, at times overlapping, in keeping with the strictures of the regulatory health authorities [10] . Volunteers were rapidly recruited and the quantitative objectives regarding cases of Covid-19 were quickly attained.

Without undue haste, the processes of data collection, analysis and verification were appreciably expedited. While the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) instituted procedures designed to fast forward the processes, there was no derogation from scientific rigor. For example, a "rolling review" consists in analyzing the data provided by laboratories every two weeks, thereby substantially shortening the overall duration of the process. As under other circumstances, only following conclusive demonstration of its quality, safety and effectiveness has a vaccine been approved by the competent independent authorities.

Whenever doubt arises on an eventual adverse effect of a given vaccine, trials are suspended.

In different cases, an independent committee analyzes the relevant data and authorizes trial Page 8 of 56 J o u r n a l P r e -p r o o f resumption in the absence of proof that the disease is in any way associated with the candidate vaccine [11] . So it was that on 6 September 2020, trials of the adenovirus-based AZD1222 vaccine developed by AstraZeneca and the University of Oxford were suspended following the appearance of myelitis in one of the participants from the United Kingdom. Only after (a) an independent committee of neurologists had concluded that the myelitis was idiopathic and (b) equally independent regulatory agencies had given their approval were the trials allowed to resume. Another example: On 12 October 2020 , due to the occurrence of an unexplained illness in one of its trial participants, the Janssen group suspended the development of its candidate vaccine AD26.COV2-S. Subsequent to evaluation of the relevant safety data by an independent supervisory committee, resumption of the trials was recommended.

Up until recently, accumulated vaccinology experience showed that the side effects of vaccines occurred a few days (at most six weeks) after vaccination. And up until now, the responsibility of a vaccine in the onset of an auto-immune disease has yet to be demonstrated.

One exception consists in the cases of narcolepsy reported after the administration of certain vaccines in the 2009 swine flu (H1N1) epidemic, particularly those using the ASO3 additive; while exceedingly rare, these cases were detected and identified by pharmacovigilance systems, the first signs having appeared a median of 3 months after the injection of vaccine [12] . In view of detecting the occurrence of this type of adverse event, the duration of monitoring in clinical trials exceeds six months [13] .

The commercialization of Covid-19 vaccines raises the question of vaccination of the volunteers included in placebo groups before the end of a trial. Once a crucial moment has J o u r n a l P r e -p r o o f passed, it becomes impossible to compare the vaccine to a placebo so as to determine not only its effectiveness, but also any delayed side effects [14] . After all, there exists a theoretical risk that exceedingly rare adverse effects (frequency < 1/10000) that remained unobserved during clinical trials may occur during a vaccination campaign. The French National Agency for Medicines and Health Products Safety (ANSM) has set up a twofold monitoring system: (a) pharmacovigilance consisting in independent medical analysis of declarations as well as regular reports and (b) pharmaco-epidemiology consisting in analysis of the data of the nationwide health data system (SNDS).

In certain cases, pre-existing immunity of natural or vaccinal origin may favor severe forms of a given infection, either (a) because pre-existing antibodies facilitate the infection of immune cells, particularly macrophages (the facilitating antibody phenomenon) or (b) because the vaccine-induced immune response proves conducive to a deleterious inflammatory reaction [15] .

One example of the "facilitating antibody" phenomenon is to be found in dengue fever; previous infection by one of the four dengue serotypes increases the risk of severe dengue fever in the event of later infection by one of the other three serotypes [15] . The same risk has been reported with regard to vaccination against dengue fever [16] , vaccinated individuals never having been infected by one of the four serotypes of the dengue virus are indeed at increased risk of a severe form of dengue fever; on the other hand, this risk has not been reported in vaccinated individuals with previous incidence of the former.

The phenomenon of deleterious macrophage polarization during inflammatory response has been observed with a viral vector vaccine based on a poxvirus, the Modified Vaccinia Ankara J o u r n a l P r e -p r o o f (MVA), in a non-human primate model for SARS-CoV infection [17] , and with other SARS-CoV vaccines in mouse models. In actuality, the deleterious antibodies were anti-spike antibodies oriented outside the Receptor Binding Domain (RBD), a fact impelling some research teams to limit themselves to this domain in their development of a vaccine. As regards SARS-CoV-2, on the other hand, no in vitro or in vivo data in animal viral infection models or in clinical trials for vaccines has suggested the existence of this risk. That said, in the development of SARS-CoV-2 vaccines, special attention has been paid to this eventual risk. The number of participants included in studies having led to market authorization for the Pfizer-BioNTech, Moderna, AstraZeneca and Sputnik V vaccines tends to demonstrate that the abovementioned adverse effect is not present during SARS-CoV-2 infection. As is the case with other hypothetically possible effects, it is monitored in real-life pharmacovigilance (phase 4).

In phase 3 trials for the Pfizer-BioNTech, Moderna and AstraZeneca vaccines, previous Covid-19 incidence was an exclusion criterium. On the contrary, a positive PCR test result for SARS-CoV-2 in nasopharyngeal swab or positive serology on screening did not occasion exclusion.

So it was that over a thousand volunteers who were shown to have had previous SARS-CoV-2 infection received at least one vaccine dose during the trials. Within the limits of this volunteer population, there was no signal of poor tolerance or occurrence of severe Covid-19. While the initial pharmacovigilance data have shown no serious incident, heightened reactogenicity has occasionally been reported [18] . The interest of (and indications for) Covid-19 vaccinations in persons recently exposed to or previously infected with SARS-CoV-2 will be considered later.

J o u r n a l P r e -p r o o f 3.9 Once a certain threshold of vaccine coverage has been attained, will circulation of the disease be limited?

During the initial phases of the vaccination campaign, the objective will be to protect persons at risk of complications and, a fortiori, to avoid deaths and hospitalizations [19, 20] . Prior to the emergence of "variants" of the virus, it appeared that herd immunity could be reached once 60% of the population would be immunized (according to the 1/R0-1 equation) [21] . The emergence of more transmissible variants (higher R0) is liable to increase the proportion of immunized persons necessary to effectively achieve "group effect", which would indirectly protect individuals who could not be vaccinated, and possibly bring the epidemic to a halt.

The group effect would also bring into play the capacity of vaccines not only to prevent the disease, but also to circumvent asymptomatic infection; at this stage, the data pertaining to this outcome of vaccination have yet to be consolidated [22, 23] (cf. the following question).

This was not the case with most of the mutations identified during the first year of the pandemic; since then, it has definitely become a justified fear.

Sequencing and continuous monitoring of circulating viral strains have been put into place on a worldwide scale, enabling researchers to follow the appearance of mutations in viral genomes and to detect the emergence of variants of concern whose mutations present epidemiological peculiarities. [28, 29] , while other studies have shown that different mutations, including E484, significantly reduce recognition of the S protein RBD by convalescent serum antibodies [30] . The Moderna laboratory has announced that in comparison with the reference strain, the serum neutralizing titers in volunteers vaccinated with their vaccine were six times lower with regard to variant B.1.351; that said, their titers remained superior to the levels considered as protective [29] . Wang et al. tested on different strains the neutralizing activity of (a) 20 convalescent plasmas, (b) the serums of 22 persons having received two doses of the Pfizer-BioNTech or Moderna vaccines, and (c) monoclonal antibodies, including two from the Regeneron® laboratory [31] ; they observed a diminution of the neutralizing activity of the antibodies with regard to the viruses presenting mutation E484K (diminution of six to eight times compared to the other variants). As for mutation N501Y, which manifested a more pronounced affinity to the ACE2 receptor, it was not associated with reduced neutralizing activity of the natural antibodies. Lastly, the phase 2/3 studies by Novavax and Johnson & Johnson/Janssen, which were partially conducted in South Africa and Brazil (the variants were already present), showed a significant but relatively limited loss of clinical effectiveness of the vaccines against the variants. More specifically, as concerns its NVX-CoV2373 vaccine, in a phase 3 trial involving 15000 participants in the United Kingdom in which the 20I/501Y.V1 be necessary, at a cadence that remains to be defined.

-It also bears mentioning that of the virus acquires mutations through which it will no longer be recognized by the post-vaccinal or post-infectious immune response, and that if the epidemic has not been mastered, it may become necessary to organize vaccination on a regular basis, using a vaccine adapted to possible immune escape variants (cf. preceding question).

Given the incubation period of Covid-19 (a median of 5 days) and the lapse of time between a 1 st vaccinal dose and the protection afforded by RNA vaccines or the AstraZeneca vaccine (2 to 3 weeks) [22, 23, 32] , vaccination is highly unlikely to represent an effective disease prevention strategy subsequent to documented exposure.

The French health authority (HAS) recommends that persons with documented SARS-CoV-2 exposure not be vaccinated before receiving screening results and/or prior to the end of a possible two-week isolation period [33] . As regards screened positive contact cases, with or without symptoms and with or without serology showing systemic immune response, the HAS recommends that vaccination preferably take place six months (not less than three months) after diagnosis of the infection, and that it consist in a single dose (cf. question 6.11) [33] . If an infection occurs after the 1 st dose of the vaccine and before the second dose has had the time to be administered, the 2 nd dose will be given only six months after diagnosis of the infection [33] . [33] . If an infection is diagnosed after the 1 st dose of a vaccine, the 2 nd dose will be postponed for six months [33] . During intramuscular injection, vaccinal RNA enters into the muscle cells, namely the myocytes [7, 36] , and then the dendritic cells, which are also present in the draining lymph nodes [37] . The messenger RNAs are internalized in the cells via the endosomes before being released by fusion between the lipid nanoparticles and the lipids of the internal side of the endosome membrane [38] . On the one hand, the RNAs stimulate innate immunity, acting as an adjuvant [39] ; on the other hand, they are translated in the cytoplasm into protein S. In the dendritic cells and the macrophages, protein S is presented to the T lymphocytes in one of two 

The high molecular weight of the RNA molecules prevents them from being freely disseminated through nuclear pores. During protein synthesis, information circulates in the J o u r n a l P r e -p r o o f DNA→RNA→protein direction by means of the nuclear export signals (NES) present on the messenger RNA molecules, the objective of these sequences being to cross the nuclear pore complex. In order to enter the nucleus, the vaccinal RNA molecules need to possess a nuclear localization sequence (NLS) [40] . Since the expression of the antigen of vaccinal interest is to be found in the cytoplasm, the mRNAs utilized in vaccines do not possess this NLS sequence.

With their reverse transcriptase enzyme, retroviruses are RNA viruses capable of "reverse transcription" (DNA from an RNA template). For example, HIV can reverse transcribe (RNA to DNA) and then be integrated in the genome by means of another viral enzyme, retroviral integrase.

Our genome contains remnants of ancient viruses that infected our long-gone ancestors, hundreds of thousands of years ago; they are known as endogenous retroviruses. Their sequences are often considered as fossils; they can generate neither reverse transcriptase nor an integrase [41] . It appears highly unlikely that vaccinal RNA could generate DNA sequences that would subsequently be incorporated into the genome of the host cell.

In DNA vaccines, nucleic acid is present in a plasmid form, which cannot be incorporated into chromosomal DNA. Moreover, the vaccine does not contain the enzyme (integrase) that would enable its integration. While other DNA delivery systems have been used with this objective in mind, they employ different technologies, and have little or nothing to do with vaccinal DNA.

As for vaccinal RNA, it cannot be injected in a "naked" form, which before being able to enter a cell would be immediately and considerably degraded. In order to avoid the phenomenon of degradation and so as to favor cellular internalization, mRNA molecules are associated with a mixture of four different lipids. One of the lipids is positively charged, the objective being to complex negatively charged mRNA molecules [42] . The three other lipids are first cholesterol, then a lipid possessing 18-carbon chains (comparable to cell membrane lipids), and lastly a lipid conjugated to a polyethylene glycol (PEG) chain. The lipid particles/mRNA have a diameter approximating 100 nm and are colloidally stable due to the effects of steric repulsion between the PEG chains. Once they have been injected, the nanoparticles fuse with the cell membranes and release RNA, which can then be translated into antigen proteins, from which the adaptive immune response originates.

PEGs constitute a class of compounds of which the molecular weight ranges from 200 to more than 10000 Da. After oral or intravenous exposure, the PEGs are excreted, mainly in changed form, in feces and urine [43] . PEGs with high molecular weight are often used in the medical industry due to their hydrosoluble and liposoluble properties. In daily life, they combat which as a result do not aggregate [44] . The anaphylactic reactions observed in mRNA vaccines are quite probably associated with preexisting anti-PEG antibodies [45] .

Up until quite recently, no duly registered RNA vaccine existed, even though researchers have been working on the subject for over 20 years [46] . The technology has continuously They can be readily and rapidly produced. They are synthesized in a laboratory, and it is not necessary to manipulate the virus. Moreover, once the vaccine has been injected, the protein of interest is naturally produced by our cells; it takes on the aspect and conformation that it usually has in the virus. Last but not least, the chosen means of delivery (injection) induces a specific and complete immune response (antibodies and lymphocyte T). This represents an appreciable advantage over inactivated or subunit vaccines, for which the immune response is incomplete (antibodies alone).

In an animal model (rhesus macaques) of SARS-CoV-2 infection, injection of two doses of 30 or 100 µg of RNA from Pfizer-BioNTech vaccine provided protection from subsequent experimental infection [48] . In the phase 1 and 2 clinical trials, the neutralizing antibody titers obtained after two vaccine doses were comparable or superior to those found in convalescent plasma. While they were generally higher on 18-to-55-year-olds than in 65-to-85-year-olds, the responses were comparable to the levels observed in convalescing patients in the two age groups. A dose of 30 μg of mRNA was chosen for the phase 2 and 3 trials [49] .

With the Moderna vaccine, injection of two doses of 10 or 100 µg of RNA rendered SARS-CoV-2 indetectable at the pulmonary level in Rhesus macaques that were vaccinated before being infected by nasal or tracheal route [50] . That said, only the 100 µg dose enabled sterilization of all the nasal and pulmonary samples. In the phase 1 trials, satisfactory levels of neutralizing antibodies similar to those found in convalescents were observed after two doses [51] .

J o u r n a l P r e -p r o o f Antibody levels were higher following the more elevated dose (100 μg), and a significant increase was observed following the second dose; a similar response has been observed in more elderly persons [52] . Lastly, persistence of the antibodies at a significant level was demonstrated for up to 119 days after the 1 st dose among the participants in these early phases, and it was higher than the level observed among convalescents [53] .

The functioning of viral vector vaccines

For thirty years, the relevant technology has been widely explored in two fields: anti-cancer and anti-infective vaccination. In this type of vaccine, a non-pathogenic virus triggers an immune response against the disease of interest [8] . 

The 

Evidence of the effectiveness of these vaccines was found in two exceedingly large phase 3 occurrence at least 10 days after the first dose [32] . As concerns the results of the Moderna vaccine trial, they were comparable after one and following two doses [22] . Primary analysis of the phase 3 AstraZeneca trials, currently available in preprint, showed vaccinal effectiveness of 76% (IC95% 59-86), without any case of Covid-19 that was severe or necessitated hospitalization starting from the 22 nd day after the 1 st dose [60] . The main argument against an increased interval between the two vaccinal doses (and, a fortiori, against utilization of a single dose) is that after a 2 nd dose, humoral immune response is 10 to 100 times greater [52, 53] , suggesting the probability of more prolonged protection, of a more For the time being, France and the majority of European countries have decided to maintain a two-dose vaccination schedule.

The phase 3 clinical trials of the RNA vaccines approved in Europe were drawn up in order to demonstrate effectiveness against the Covid-19 disease (symptomatic SARS-CoV-2 infection), and only in the event of symptoms did the relevant protocols stipulate a search for infection [22, 32] . published, some of the participants underwent systematic weekly testing, the objective being to detect asymptomatic infections [23] . A half-dose/full dose regimen afforded 58% protection from asymptomatic infections (CI95%: 1-83%); on the other hand, a full dose/full dose regimen failed to provide significant protection. According to primary analysis of phase 3 trials (available in preprint format), vaccination lowered the PCR positive rate by 67% (CI95% 49-78) after the 1 st dose and by 50% (CI95% 38-59) after the two doses [60] .

Before being able to assess (and to understand) the possible effect of certain vaccines on transmission, it will be necessary to collect complementary clinical information and mucous immunity data. Even though symptomatic infected persons are obviously highly implicated in transmission of the virus, results concerning vaccine effectiveness against asymptomatic infection and transmission will probably be less spectacular than their effect on the symptomatic forms.

An overwhelming majority of the adverse events observed during clinical trials of RNA vaccines appeared the day after vaccination and generally lasted for fewer than 3 days [22, 32] . In many cases, the events represented signs of reactogenicity: injection site reaction, asthenia, headache, myalgia, chills or fever. Systemic effects were the most frequent after the 2 nd dose and in persons under 65 years of age; more often than not, they were minimum to moderate. While paracetamol intake remains possible, for the time being it is not recommended as a preventive measure.

The data on the frequency of reactogenicity symptoms in the two trials came from a "solicited" More frequent occurrence of axillary adenopathy in the group of vaccinated volunteers (0.3 and 1.1% in the Pfizer-BioNTech and Moderna trials respectively) than in those having received the placebo was likewise noteworthy. In only one case was the adenopathy classified as a "severe adverse effect".

Several cases of facial paralysis (Bell's palsy) have been reported in the clinical trials of Pfizer-BioNTech and Moderna [22, 32] . In the Pfizer-BioNTech trial, there were four cases of facial paralysis, two of which were ascribed to the vaccine, as opposed to none in the placebo group.

Facial paralysis appeared in one case on day 37 after dose 1 (the participant did not receive dose 2), and on days 3, 9 and 48 after dose 2 in the three other cases. In the Moderna trial, there were three cases in the vaccinated group, as opposed to one case in the placebo group.

In the AstraZeneca trials, three cases of facial paralysis occurred in the two groups [23] . In which is estimated at 1-5 per 10000 treatments [67] ). More than 90% of the reported events involved women, and approximately one third of the affected persons presented with anaphylaxis history. Median time elapsed between vaccine injection and symptom occurrence was 10 minutes [65] . Initial French pharmacovigilance data show four severe anaphylaxis cases for approximately 950,000 doses [64] .

To conclude, the cumulative data are reassuring; the benefit/risk ratio in populations for which vaccination has been recommended is distinctly favorable. It bears mentioning that the mortality rate in cases of SARS-CoV-2 infection is an estimated at 0.5-1.4%, and that it exceeds 10% in persons over 70 years of age.

Vaccination is contraindicated for persons with hypersensitivity to a vaccine component, particularly PEG, or with a history of allergy polysorbate (risk of cross-allergy or cross-reactivity with the PEG contained in the vaccine). PEG or macrogol, a polyether compound, is used in different parenteral medicines (cf. question 4.7, non-exhaustive list). It can also be found in the coating of numerous treatments (antibiotics and NSAIDs in particular); in an exceptional situation, PEG is itself the allergen.

Given the reassuring data collected since worldwide launching of the immunization campaign, J o u r n a l P r e -p r o o f the Fédération française d'allergologie has recommended that allergy or anaphylaxis history not constitute a systematic contraindication to vaccination [68] . The policy to be adopted should take into account a description of (a) the allergy, (b) the substance currently or potentially at issue, and (c) the conclusions of a possible overall allergy assessment: -Lastly, several preprints have shown that in the target population, a single vaccine dose triggers a substantial rise in IgG and IgA titers and in those of neutralizing antibodies [18, 77, 78] . In one of these studies, vaccinal injection procured neutralizing titers against divergent strains (variant 20H/501Y.V2 and SARS-CoV-1) [78] . A real-life study on the immunogenicity of the 1 st dose of the Pfizer-BioNTech vaccine involving 514 health professionals revealed antibody titers ten times higher than those found in persons with an infection history [79] .

It is in this context that on 12 February 2021, the HAS recommended that injection for nonimmunosuppressed persons with a history of symptomatic or asymptomatic SARS-CoV-2

infection not be administered during the first six months, and that it consist in only one injection, to be considered as a booster shot [33] . The vaccines stimulate the innate immune system by interacting with the toll-like receptors, inducing an "alarm signal" and the expression of certain cytokines. Pro-inflammatory cytokines and interferons are conducive to the recruitment and activation of immune cells, and also to the acquisition of immune memory. A hypothesis has been put forward according to which immune response could be deleterious in individuals seemingly predisposed to inflammatory reactions and, possibly, to autoimmune disease; as of now, this risk remains theoretical, and the above-mentioned phenomena have never been observed with regard to any vaccine.

In view of attenuating this phenomenon, and of ensuring that it does not entail destruction of the RNA before it has had the time to be translated into protein, the RNA in the Pfizer-BioNTech vaccines is composed of nucleotides slightly different from natural nucleotides (pseudo-uridines) [84] . CureVac has chosen not to modify the nucleotides.

In the phase 2/3 clinical trial of Pfizer-BioNTech, a history of dysimmune disease was not an As regards early administration of the 2 nd dose, according to the CDC it can occur up until three or four days before (the recommended) D21 or D28 [34] . If by mistake it were to occur earlier, J o u r n a l P r e -p r o o f it would be necessary to have it repeated.

As regards the possibility of late administration of the 2 nd dose of the Pfizer-BioNTech vaccine, on 7 January the French ANSM issued the authorization and on 22 January the HAS put forward the recommendation to postpone the 2 nd vaccination up until D42, the objective being to enlarge single-dose vaccination coverage among target populations in a constraining context [87, 88] . Their argumentation was essentially based on the fact that some participants included in clinical trials received their 2 nd dose of a vaccine more than 21 days (and up to 42 days) after the first, and that vaccinal effectiveness was visible starting on D12, that is to say well before administration of the 2 nd dose. As for the WHO, on 5 January it pronounced itself in favor of an interval ranging from 21 to 28 days between the two doses of Pfizer-BioNTech, and declared that under exceptional circumstances, the interval could be prolonged, but without exceeding 42 days [89] . In the absence of certified data on the duration of the protection afforded by the 1 st dose of a vaccine, and given the risk that in the face of emerging variants, a single dose not enable development of a sufficient immune response, on 26 January the French health minister announced that the 2 nd dose would have to be administered between D21 and D28 [90] .

In actual practice, if the recommended interval between the two doses were to be exceeded, the second dose would have to be administered as expeditiously as possible, without their being any need for more than two doses.

Errors of administration must be reported in pharmacovigilance.

Due to the highly theoretical risk of interference between the immune responses provoked by J o u r n a l P r e -p r o o f the two vaccines, a minimal interval of 14 days between an RNA-based vaccine and another vaccine is recommended. However, in the event that this time interval were not to be observed, it would not be necessary to modify the schedule and/or administer a supplementary dose of one of the two vaccines.

At present, there do not exist any vaccination data concerning infected persons having received monoclonal antibodies or convalescent plasma in the context of Covid-19 treatment.

Given the estimated half-life of these treatments and a number of observations suggesting that reinfection during the six months following the initial infection is infrequent, it is recommended to postpone vaccination for at least 90 days.

For persons receiving polyvalent immunoglobulins (by intravenous or subcutaneous route), RNA vaccine administration is possible, without it being necessary to observe a given time interval before or after infusion. As of now, the amounts of anti-SARS-CoV-2 antibodies contained in these treatments are negligible and do not seem liable to antagonize the development of a protective antibody response. 

vaccination?

This point is developed in paragraphs 3.12 and 6.11.

No. The vaccine must be injected intramuscularly; that is the route of administration having been used in clinical trials.

In subjects presenting with primary hemostasis disorders or coagulation, and in persons taking anticoagulants, low-volume vaccination can be carried out in the deltoid muscle with a thin needle (ideally 25G, and a length of 25 mm for a normal-sized injection site), followed by pronounced and prolonged, facilitated compression (2 minutes). Persons presenting with highly severe hemostasis disorders or coagulation can be vaccinated on a case-by-case basis, if the possible benefits clearly outweigh the drawbacks associated with administration [91] .

Use of the subcutaneous route exposes the patient to the risks of less satisfactory immunogenicity and heightened local reactogenicity [92] .

In preclinical trials of nucleic acid vaccines, the first and second (booster) injections are carried out in the same muscle. The protocols for the phase 3 trials of the RNA and the AstraZeneca 

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains

Next-generation vaccine platforms for COVID-19

Viral emerging diseases: challenges in developing vaccination strategies

World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

mRNA vaccines -a new era in vaccinology

Vaccinology in the post-COVID-19 era

Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother

Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine

Covid-19 : AstraZeneca et J&J reprennent leurs essais cliniques. Industrie Pharma

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

Planning for COVID-19 vaccines safety surveillance

Placebo-Controlled Trials of Covid-19 Vaccines -Why We Still Need Them

Intrinsic antibodydependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine

Evaluation des stratégies vaccinales COVID-19 avec un modèle mathématique populationnel

COVID-19 herd immunity: where are we?

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

mRNA vaccineelicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Stratégie de vaccination contre le SARS-CoV-2 : Vaccination des personnes ayant un antécédent de Covid-19. 12 février 2021

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA

Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction

Visualization of early events in mRNA vaccine delivery in non-human primates via PET/CT and nearinfrared imaging

Probing the mechanism of action of cationic lipid/DNA lipoplxes at a nanometric scale

Proximity ligation assays for in situ detection of innate immune activation: focus on in vitrotranscribed mRNA

Nuclear localization signals for four distinct karyopherin-β nuclear import systems

Endogenous Retroviruses in the Genomics Era

Design of ionizable lipids to overcome the limiting step of endosomal escape: Application in the intracellular delivery of mRNA, DNA and siRNA

Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products

Sterically stabilized BGTC-based lipoplexes: structural features and gene transfection into the mouse airways in vivo

Preexisting anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Mechanism of action of mRNAbased vaccines

DNA vaccine and its importance in veterinary. Dairy and

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Covid-19 : MSD abandonne deux candidats-vaccins, dont celui développé avec l'Institut Pasteur

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Stratégie de la vaccination contre la Covid-19 -Place du

Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Etiology, diagnosis, and management of facial palsy: 2000 patients at a facial nerve center

Point de situation sur la surveillance des vaccins contre la

Reports of Anaphylaxis After Receipt of mRNA COVID-19

Epub ahead of print

Nokleby H. Vaccination and anaphylaxis

The facts about penicillin allergy: a review

Vaccination contre la Covid-19. 4 février 2021

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Neutralizing antibody titres in SARS-CoV-2 infections

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Establishment of an African green monkey model for COVID-19 and protection against reinfection

Antibody status and incidence of SARS-CoV-2 infection in health care workers

Covid-19: Past infection provides 83% protection for five months but may not stop transmission, study finds

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months

Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2

Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers

The American College of Obstetricians and Gynecologists (ACOG)

Vaccination considerations for people who are pregnant or breastfeeding

Oxford University/AstraZeneca covid-19 vaccine approved

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Vaccination contre la Covid-19 des patients atteints de maladies inflammatoires à médiation immune. 23 janvier 2021

Préconisations de priorisation des patients atteints de cancer pour la vaccination contre le SARS-CoV-2. 25 janvier 2021

Avis de l'ANSM concernant la seconde dose du vaccin Comirnaty Pfizer BioNtech. 7 janvier 2021

Modification du schéma vaccinal contre le SARS-CoV-2 dans le nouveau contexte épidémique. 22 janvier 2021

Critical preparedness, readiness and response. Interim recommendations for use of the Pfizer-BioNTech COVID-February 08

Intervention Olivier Véran : Délais vaccination entre deux doses. 26 janvier 2021

Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs

Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature